ClinicalTrials.gg

Program

AP301 peptide

Also written as “AP301”, “AP301 Low Dose” and “Solnatide 25 mg powder for reconstitution for solution for inhalation”.

Its studies are mostly in Hyperphosphatemia · Renal Insufficiency, Chronic · Primary Graft Dysfunction · Acute Lung Injury, led by 3 companies.

Furthest: phase 3, since Jun 20, 20126 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Apeptico Forschung und Entwicklung30 open or runningphase 2since Jun 20, 2012Jun 20, 2012none ahead
Alebund Pharmaceuticals21 open or runningphase 3since Mar 19, 2025Mar 19, 2025none ahead
Alebund Pty10 open or runningphase 1since Oct 17, 2023Oct 17, 2023none ahead

Also a collaborator on its studies: fortrea.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 20, 2012First study: phase 2 study in Acute Lung InjuryNew to Apeptico Forschung und EntwicklungApeptico Forschung und Entwicklung · NCT01627613 · 40 enrolled · Austria
  2. Mar 21, 2014Phase 2 study in PGD Primary Graft DysfunctionApeptico Forschung und Entwicklung · NCT02095626 · 20 enrolled · Austria
  3. Apr 23, 2018Phase 2 study in ARDSApeptico Forschung und Entwicklung · NCT03567577 · 92 enrolled · Austria, Germany
  4. Oct 17, 2023Alebund Pty's first study: phase 1 study in Healthy SubjectsNew to Alebund PtyAlebund Pty · NCT06100627 · 32 enrolled · Australia
  5. Mar 19, 2025Alebund Pharmaceuticals's first study: phase 3 study in HyperphosphatemiaNew to Alebund PharmaceuticalsAlebund Pharmaceuticals · NCT06933472 · 264 planned · United States, China
  6. Jun 5, 2025Phase 3 study in Renal Insufficiency, ChronicAlebund Pharmaceuticals · NCT07030595 · 474 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07030595Renal Insufficiency, Chronic · China3CompletedAlebund PharmaceuticalsOct 2, 2024474
NCT06933472Hyperphosphatemia · United States, China3RecruitingAlebund PharmaceuticalsJun 20, 2026264
NCT06100627Healthy Subjects · Australia1CompletedAlebund PtyFeb 8, 202432
NCT03567577ARDS · Austria, Germany2CompletedApeptico Forschung und EntwicklungDec 27, 202492
NCT02095626PGD Primary Graft Dysfunction · Austria2CompletedApeptico Forschung und EntwicklungMar 201520
NCT01627613Acute Lung Injury · Austria2CompletedApeptico Forschung und EntwicklungMay 201440

How it is read

Names in the registry

  • “AP301”, 4 entries
  • “AP301 Low Dose”, 2 entries
  • “Solnatide 25 mg powder for reconstitution for solution for inhalation”, 1 entry
  • “AP-301”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.